Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | The need for context-sensitive endpoint frameworks beyond overall survival

Antonella Cardone • 25 Oct 2026
ESMO 2026
General

Antonella Cardone, Cancer Patients Europe, Brussels, Belgium, discusses a multidisciplinary evaluation of when overall survival is insufficient as an oncology endpoint, drawing on regulatory and health technology assessment appraisals. Alternative endpoints can provide meaningful evidence where overall survival is immature or confounded, yet are interpreted differently across jurisdictions. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Antonella Cardone

Health technology assessment disparities & cancer treatment access in Europe
1:48
Health technology assessment disparities & cancer treatment access in Europe
Antonella Cardone • 25 Oct 2026
Patient-reported evidence and the role of lived experience in cancer care
1:49
Patient-reported evidence and the role of lived experience in cancer care
Antonella Cardone • 25 Oct 2026

Related Videos

Drug price competition and the potential for tendering in oncology care
1:34
Drug price competition and the potential for tendering in oncology care
Daniel Goldstein • 23 Oct 2026
What financial challenges patients and healthcare systems face in oncology?
1:11
What financial challenges patients and healthcare systems face in oncology?
Daniel Goldstein • 23 Oct 2026
How can we enhance the efficacy of TILs therapy in solid tumors?
2:27
How can we enhance the efficacy of TILs therapy in solid tumors?
Paolo Ascierto • 23 Oct 2026
Cellular therapy advances and regulatory approvals in oncology in 2026
1:57
Cellular therapy advances and regulatory approvals in oncology in 2026
Paolo Ascierto • 23 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals